T. Rowe Price Associates

T. Rowe Price Associates’s Spyre Therapeutics SYRE Stock Holding History

T. Rowe Price Associates’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$80.6M	Sell	1,598,730 -3,152	-0.2%	-$119K	0.01%	655
2025 Q4	$52.5M	Buy	1,601,882 +981,262	+158%	+$25.6M	0.01%	807
2025 Q3	$10.4M	Sell	620,620 -309,861	-33%	-$5.05M	﹤0.01%	1219
2025 Q2	$13.9M	Buy	930,481 +681,939	+274%	+$10.1M	﹤0.01%	1050
2025 Q1	$4.01M	Sell	248,542 -257,908	-51%	-$5.37M	﹤0.01%	1315
2024 Q4	$11.8M	Buy	506,450 +77,323	+18%	+$2.27M	﹤0.01%	1121
2024 Q3	$12.6M	Buy	429,127 +121,151	+39%	+$3.37M	﹤0.01%	1100
2024 Q2	$7.24M	Buy	307,976 +229,447	+292%	+$7.74M	﹤0.01%	1154
2024 Q1	$2.98M	Buy	+78,529	New	+$2.28M	﹤0.01%	1389

Other funds holding SYRE

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return